Categories: ImplantsNews

X-Bolt Receives Prestigious ‘Best Technology in Spine’ Award from Orthopedics This Week

DUBLIN, Sept. 16, 2024 /PRNewswire/ — X-Bolt Orthopedics, an emerging innovator of bone fixation implants in orthopedics, has been awarded the Best Technology In Spine Award for 2024/2025 by Orthopedics This Week. This award honors the unsung heroes in the world of medical technology — the inventors, engineers, and innovators who dedicate countless hours to advancing spine surgery.

The DragonBoltÔ Pedicle Screw by X-Bolt was recognized for its potential to solve a critical clinical problem: pedicle screw loosening, which affects 23% of osteoporotic bone patients undergoing non-augmented procedures. Augmented fixation also suffers from cement leakage in 22% of cases and often Bone Cement Implantation Syndrome, an important cause of intraoperative mortality.

The DragonBolt’s groundbreaking design aims to drastically reduce these complications, offering surgeons and patients an alternative that provides superior fixation without the drawbacks of current solutions. In validated Finite Element Modeling testing, traditional pedicle screws were shown to cause 400% more bone damage compared to X-Bolt’s DragonBolt after just 25 cycles of cyclic loading.

A distinguished panel of practicing spine and neurosurgeons selected the DragonBolt for this award, including:

  • Juan Uribe, MD
  • Kris Radcliff, MD
  • Isaac Moss, MDCM, MASc, FRCSC
  • Stephen Hochschuler, MD
  • Michael Wang, MD, FACS
  • Peter Derman, MD, MBA

“We’re honored to receive this recognition, as it underscores the potential of X-Bolt’s expanding bolt technology in the osteoporotic spine,” said Brian Thornes, Founder & CEO of X-Bolt. “DragonBolt is designed for strength and reversibility, available in multiple sizes, and can be seamlessly integrated into any existing pedicle screw system. We’re eager to see how this innovative solution will be scaled to meet the evolving needs of spinal surgeons.”

For more information about X-Bolt’s DragonBolt and other orthopedic solutions, visit www.x-bolt.com 

About X-Bolt:

X-Bolt is an innovator of medical devices focused on providing superior fixation solutions with its patented expanding bolt technology. X-Bolt’s technology has demonstrated the lowest published cut-out rates for hip fracture. Investors in X-Bolt include BVP Partners, AIB Seed Capital, Ascentifi, Amalfi, MedTech angel group and several Irish orthopedic surgeons.

About Spine Technology Awards: Presented by Orthopedics This Week and RRY Publications, the Spine Technology Awards bring increased recognition to innovative spine surgery products and their teams and inventors. The Awards are presented in the fall each year at the North American Spine Society Annual Meeting. Past winners can be seen at http://spineawards.com.

Media contact: Phil Kemp, President & Chief Operating Officer, philip.kemp@x-bolt.com, Phone +1 845 309 2471

Photo – https://healthtechnologynet.com/wp-content/uploads/2024/09/X_Bolt_Spine_Award_2024.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/x-bolt-receives-prestigious-best-technology-in-spine-award-from-orthopedics-this-week-302249198.html

SOURCE X-Bolt Orthopedics

Staff

Recent Posts

Bemax Receives New Purchase Order

Total purchase order value of $972,135 Initial payment of $114,000 receivedDeliveries to be completed December…

2 hours ago

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the…

3 hours ago

Procaps Issues Shareholder Letter Update

MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC)…

3 hours ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s…

3 hours ago

Accolade to Announce Fiscal Second Quarter 2025 Financial Results

SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will…

3 hours ago

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to…

3 hours ago